San Francisco-based Spruce Biosciences closed on a Series B financing round valued at $88 million, as the company develops tildacerfont for the rare genetic disorder congenital adrenal hyperplasia (CAH).
https://www.pharmalive.com/wp-content/uploads/2020/02/Spruce-Series-B-BioSpace-2-20-20.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2020-02-20 12:13:172020-02-21 13:14:55Spruce Biosciences Closes on $88 Million Series B Round, Advancing CAH Program